Effectiveness of the combination elvitegravir/cobicistat/tenofovir/emtricitabine (EVG/COB/TFV/FTC) plus darunavir among treatment-experienced patients in clinical practice:: a multicentre cohort study.

I. Suárez-García; C. Moreno; M. Ruiz-Algueró; MJ. Pérez-Elías; M. Navarro; M. Díez-Martínez; Pompeyo Viciana; L. Pérez-Martínez; Miguel Górgolas-Hernández-Mora; C. Amador; MA. de Zárraga; I. Jarrin; Roberto Muga Bustamante

doi:10.1186/s12981-020-00302-2

Effectiveness of the combination elvitegravir/cobicistat/tenofovir/emtricitabine (EVG/COB/TFV/FTC) plus darunavir among treatment-experienced patients in clinical practice: a multicentre cohort study.

I. Suárez-García, C. Moreno, M. Ruiz-Algueró, MJ. Pérez-Elías, M. Navarro, M. Díez-Martínez, Pompeyo Viciana, L. Pérez-Martínez, Miguel Górgolas-Hernández-Mora, C. Amador, MA. de Zárraga, I. Jarrin, Roberto Muga Bustamante

Departament de Medicina

Producció científica: Contribució a revista › Article › Recerca › Avaluat per experts

1 Citació (Scopus)

Resum

Background
The aim of this study was to investigate the effectiveness and tolerability of the combination elvitegravir/cobicistat/tenofovir/emtricitabine plus darunavir (EVG/COB/TFV/FTC + DRV) in treatment-experienced patients from the cohort of the Spanish HIV/AIDS Research Network (CoRIS).

Methods
Treatment-experienced patients starting treatment with EVG/COB/TFV/FTC + DRV during the years 2014–2018 and with more than 24 weeks of follow-up were included. TFV could be administered either as tenofovir disoproxil fumarate or tenofovir alafenamide. We evaluated virological response, defined as viral load (VL)
Results
We included 39 patients (12.8% women). At baseline, 10 (25.6%) patients had VL
Conclusions
EVG/COB/TFV/FTC + DRV was well tolerated and effective in treatment-experienced patients with undetectable viral load as a simplification strategy, allowing once-daily, two-pill regimen with three antiretroviral drug classes. Effectiveness was low in patients with detectable viral loads.

Idioma original	Anglès
Nombre de pàgines	7
Revista	AIDS Res Ther
Volum	17
Número	45
DOIs	https://doi.org/10.1186/s12981-020-00302-2
Estat de la publicació	Publicada - de jul. 2020

SDG de les Nacions Unides

Aquest resultat contribueix als següents objectius de desenvolupament sostenible.

Accés al document

10.1186/s12981-020-00302-2Llicència: Creative Commons Reconeixement

https://ddd.uab.cat/record/293966

Com citar-ho

Suárez-García, I., Moreno, C., Ruiz-Algueró, M., Pérez-Elías, MJ., Navarro, M., Díez-Martínez, M., Viciana, P., Pérez-Martínez, L., Górgolas-Hernández-Mora, M., Amador, C., de Zárraga, MA., Jarrin, I., & Muga Bustamante, R. (2020). Effectiveness of the combination elvitegravir/cobicistat/tenofovir/emtricitabine (EVG/COB/TFV/FTC) plus darunavir among treatment-experienced patients in clinical practice: a multicentre cohort study. AIDS Res Ther, 17(45). https://doi.org/10.1186/s12981-020-00302-2

@article{f3d2937f560543d2a5519f1269ca4619,

title = "Effectiveness of the combination elvitegravir/cobicistat/tenofovir/emtricitabine (EVG/COB/TFV/FTC) plus darunavir among treatment-experienced patients in clinical practice:: a multicentre cohort study.",

abstract = "BackgroundThe aim of this study was to investigate the effectiveness and tolerability of the combination elvitegravir/cobicistat/tenofovir/emtricitabine plus darunavir (EVG/COB/TFV/FTC + DRV) in treatment-experienced patients from the cohort of the Spanish HIV/AIDS Research Network (CoRIS).MethodsTreatment-experienced patients starting treatment with EVG/COB/TFV/FTC + DRV during the years 2014–2018 and with more than 24 weeks of follow-up were included. TFV could be administered either as tenofovir disoproxil fumarate or tenofovir alafenamide. We evaluated virological response, defined as viral load (VL) ResultsWe included 39 patients (12.8% women). At baseline, 10 (25.6%) patients had VL ConclusionsEVG/COB/TFV/FTC + DRV was well tolerated and effective in treatment-experienced patients with undetectable viral load as a simplification strategy, allowing once-daily, two-pill regimen with three antiretroviral drug classes. Effectiveness was low in patients with detectable viral loads.",

keywords = "HIV infection, Highly active antiretroviral therapy, Cohort studies, Darunavir",

author = "I. Su{\'a}rez-Garc{\'i}a and C. Moreno and M. Ruiz-Alguer{\'o} and MJ. P{\'e}rez-El{\'i}as and M. Navarro and M. D{\'i}ez-Mart{\'i}nez and Pompeyo Viciana and L. P{\'e}rez-Mart{\'i}nez and Miguel G{\'o}rgolas-Hern{\'a}ndez-Mora and C. Amador and {de Z{\'a}rraga}, MA. and I. Jarrin and {Muga Bustamante}, Roberto",

year = "2020",

month = jul,

doi = "10.1186/s12981-020-00302-2",

language = "English",

volume = "17",

number = "45",

}

Suárez-García, I, Moreno, C, Ruiz-Algueró, M, Pérez-Elías, MJ, Navarro, M, Díez-Martínez, M, Viciana, P, Pérez-Martínez, L, Górgolas-Hernández-Mora, M, Amador, C, de Zárraga, MA, Jarrin, I & Muga Bustamante, R 2020, 'Effectiveness of the combination elvitegravir/cobicistat/tenofovir/emtricitabine (EVG/COB/TFV/FTC) plus darunavir among treatment-experienced patients in clinical practice: a multicentre cohort study.', AIDS Res Ther, vol. 17, núm. 45. https://doi.org/10.1186/s12981-020-00302-2

Effectiveness of the combination elvitegravir/cobicistat/tenofovir/emtricitabine (EVG/COB/TFV/FTC) plus darunavir among treatment-experienced patients in clinical practice: a multicentre cohort study. / Suárez-García, I.; Moreno, C.; Ruiz-Algueró, M. et al.
In: AIDS Res Ther, Vol. 17, Núm. 45, 07.2020.

Producció científica: Contribució a revista › Article › Recerca › Avaluat per experts

TY - JOUR

T1 - Effectiveness of the combination elvitegravir/cobicistat/tenofovir/emtricitabine (EVG/COB/TFV/FTC) plus darunavir among treatment-experienced patients in clinical practice:

T2 - a multicentre cohort study.

AU - Suárez-García, I.

AU - Moreno, C.

AU - Ruiz-Algueró, M.

AU - Pérez-Elías, MJ.

AU - Navarro, M.

AU - Díez-Martínez, M.

AU - Viciana, Pompeyo

AU - Pérez-Martínez, L.

AU - Górgolas-Hernández-Mora, Miguel

AU - Amador, C.

AU - de Zárraga, MA.

AU - Jarrin, I.

AU - Muga Bustamante, Roberto

PY - 2020/7

Y1 - 2020/7

N2 - BackgroundThe aim of this study was to investigate the effectiveness and tolerability of the combination elvitegravir/cobicistat/tenofovir/emtricitabine plus darunavir (EVG/COB/TFV/FTC + DRV) in treatment-experienced patients from the cohort of the Spanish HIV/AIDS Research Network (CoRIS).MethodsTreatment-experienced patients starting treatment with EVG/COB/TFV/FTC + DRV during the years 2014–2018 and with more than 24 weeks of follow-up were included. TFV could be administered either as tenofovir disoproxil fumarate or tenofovir alafenamide. We evaluated virological response, defined as viral load (VL) ResultsWe included 39 patients (12.8% women). At baseline, 10 (25.6%) patients had VL ConclusionsEVG/COB/TFV/FTC + DRV was well tolerated and effective in treatment-experienced patients with undetectable viral load as a simplification strategy, allowing once-daily, two-pill regimen with three antiretroviral drug classes. Effectiveness was low in patients with detectable viral loads.

AB - BackgroundThe aim of this study was to investigate the effectiveness and tolerability of the combination elvitegravir/cobicistat/tenofovir/emtricitabine plus darunavir (EVG/COB/TFV/FTC + DRV) in treatment-experienced patients from the cohort of the Spanish HIV/AIDS Research Network (CoRIS).MethodsTreatment-experienced patients starting treatment with EVG/COB/TFV/FTC + DRV during the years 2014–2018 and with more than 24 weeks of follow-up were included. TFV could be administered either as tenofovir disoproxil fumarate or tenofovir alafenamide. We evaluated virological response, defined as viral load (VL) ResultsWe included 39 patients (12.8% women). At baseline, 10 (25.6%) patients had VL ConclusionsEVG/COB/TFV/FTC + DRV was well tolerated and effective in treatment-experienced patients with undetectable viral load as a simplification strategy, allowing once-daily, two-pill regimen with three antiretroviral drug classes. Effectiveness was low in patients with detectable viral loads.

KW - HIV infection

KW - Highly active antiretroviral therapy

KW - Cohort studies

KW - Darunavir

U2 - 10.1186/s12981-020-00302-2

DO - 10.1186/s12981-020-00302-2

M3 - Article

VL - 17

JO - AIDS Res Ther

JF - AIDS Res Ther

IS - 45

ER -

Effectiveness of the combination elvitegravir/cobicistat/tenofovir/emtricitabine (EVG/COB/TFV/FTC) plus darunavir among treatment-experienced patients in clinical practice: a multicentre cohort study.

Resum

SDG de les Nacions Unides

Accés al document

Fingerprint

Com citar-ho